The addition of Research Across America's sites means that Synexus can now offer extra capacity, particular U.S. market expertise and therapeutic experience.
Synexus has purchased Research Across America (RAA) for an undisclosed sum. RAA was founded in 1989 by Dr. Jeffrey Adelglass, and has grown from a single location to multiple dedicated research sites across the U.S. Its sites have conducted over 2,000 clinical trials.
Synexus already owns 25 research sites in 10 countries. The addition of RAA’s sites means that it can now offer extra capacity, particular U.S. market expertise and therapeutic experience.
“Synexus already has a strong international footprint. This latest acquisition is an important one for Synexus as it marks our entry into the US market, giving us truly global capability,” noted CEO Christophe Berthoux. “We spent a great deal of time considering an appropriate partner and selected Research Across America as it has a number of synergies with the Synexus model. In addition, by adding these sites to our network we have also gained expertise in areas, such as dermatology and generics, enabling us to further support our client base.”
Read the full article.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.